SARS-CoV-2-Induced Damage on the Cardiovascular System: Molecular Mechanisms

Mel·lina Pinsach-Abuin and Ramon Brugada Terradellas

Cardiovascular Genetics Center, Institut d’Investigació Biomèdica de Girona, Spain

Abstract: Since its emergence in late December 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) - the causative agent of coronavirus disease 2019 (COVID-19) - has spread rapidly world-wide, becoming a global pandemic in March 2020 that is still active. In addition to the severe pulmonary damage, clinical studies have reported that COVID-19 is associated with the development of cardiovascular alterations such as myocardial injury, particularly in its most severe manifestations. At the same time, pre-existing cardiovascular conditions in COVID-19 cases have been related to an increased risk of adverse outcomes. To date, several mechanisms have been described to participate in the development of cardiovascular damage related to COVID-19, including direct SARS-CoV-2 infection of the cardiovascular system, Angiotensin-Converting Enzyme 2 (ACE2) downregulation, cytokine storm, coagulation abnormalities, hypoxia and drug-induced cardiotoxicity. However, the large amount of information gathered so far makes it difficult to keep up with this new pandemic. In the present review, we provide a clear insight of the extensive literature available and summarize the current understanding of COVID-19-related mechanisms behind SARS-CoV-2-induced damage to the cardiovascular system.

Keywords: SARS-CoV-2, Infection, COVID-19, ACE2, Cytokine Storm, Myocardial Injury

Introduction

Coronavirus disease 2019 (COVID-19) is a novel infectious disease of the human respiratory system caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (Wu et al., 2020a; Zhou et al., 2020; Zhu et al., 2020). Coronavirus are enveloped RNA particles that normally cause mild to moderate respiratory illnesses, such as the common cold. However, some coronaviruses may lead to severe and fatal respiratory infections. SARS-CoV-2 is the newest member of the β-coronavirus family like the two previous coronaviruses that became respiratory-disease epidemics, mainly occurring in China and Saudi Arabia (Wu et al., 2020b; Zhou et al., 2020; Zhu et al., 2020). These include the SARS-CoV, the causal agent of SARS and the Middle East Respiratory Syndrome (MERS)-CoV, the causal agent of MERS. Since its emergence in Wuhan province in China in late December 2019 (Zhu et al., 2020), SARS-CoV-2 has spread rapidly worldwide resulting in over 86 million confirmed COVID-19 cases with more than 1.8 million deaths as of January 7, 2021 (WHO, 2021).

SARS-CoV-2 is mainly transmitted human-to-human by inhalation of respiratory droplets or aerosols spread by coughing or sneezing from an infected individual. COVID-19 has a mean incubation period of 5.2 days, with an inferred infectiousness profile starting from 12.3 days (95% CI, 5.9-17.0 days) before symptom onset and peaking at symptom onset (95% CI, -0.9-0.9 days) (He et al., 2020). The primary symptoms of COVID-19 are fever, dry cough, fatigue and dyspnea. It generally ranges from asymptomatic to mild disease in 80% of infected cases; although approximately 15% of cases progress to severe COVID-19 and about 5% eventually become critically ill (Huang et al., 2020). Although the probability to develop severe complications and death in COVID-19 is higher in the elderly and patients with pre-existing conditions – such as hypertension, cardiovascular disease, diabetes and obesity- (Li et al., 2020), several cases of young and healthy individuals developing acute symptoms have been notified (WHO, 2021). Respiratory complications, such as viral pneumonia and Acute Respiratory Distress Syndrome (ARDS) are the dominant clinical manifestation in severe COVID-19 cases and the main
cause of death (Polidoro et al., 2020). Apart from respiratory symptoms, early clinical studies describe that about 20-25% of COVID-19 patients also develop cardiac complications -such as myocarditis, arrhythmias, thromboembolic events and heart failure-, even in the absence of previous cardiovascular conditions (Guzik et al., 2020; Huang et al., 2020). In fact, cardiac damage, as reflected by high troponin levels in the blood, is a common feature observed within hospitalized COVID-19 cases and represents a risk factor for mortality (Zou et al., 2020). Moreover, clinical studies conducted to date have identified that, although a proportion of COVID-19 patients develop cardiac complications, the presence of a pre-existing Cardiovascular Disease (CVD) is a highly prevalent comorbidity among patients with COVID-19, which has been associated with poor prognosis and high mortality rate (Huang et al., 2020; F. Zhou et al., 2020).

In this review we summarize the relationship between SARS-CoV-2 infection and cardiac complications and discuss possible mechanisms underlying SARS-CoV-2-induced damage to the cardiovascular system. It is important to highlight that given the novelty of COVID-19, this review contains information based on preliminary research that needs to be interpreted cautiously.

**Search Methods**

To write the present review, we gathered from PubMed and Google all research and review articles, bulletins from governmental and health organizations and expert reports published since the emergence of the COVID-19 pandemic. We searched for “SARS-CoV-2”, “COVID-19”, “ACE2” and “cytokine storm” in combination with “cardiovascular”, “myocardial injury” and “heart failure”. We also examined relevant references for previous studies about the two other β-coronaviruses causing respiratory-disease epidemics (SARS-CoV and MERS-CoV).

**SARS-CoV-2 Pathogenesis**

SARS-CoV-2 is a spherical particle delineated by a lipid bilayer where the structural Membrane (M), Envelope (E) and Spike (S) proteins are anchored (Jaimes et al., 2020; Masters, 2006) (Fig. 1a). SARS-CoV-2 genome is a positive-sense single-stranded RNA molecule (ssRNA) surrounded by the nucleocapsid (N) proteins, that shares 96.2 and 79.6% sequence identity with bat coronavirus RaTG13 and SARS-CoV, respectively (F. Wu et al., 2020a; P. Zhou et al., 2020). Given the genetic similarity between SARS-CoV and SARS-CoV-2, the two viruses share many biological features. Both viruses infect human cells through the binding of the S protein to the human Angiotensin-Converting Enzyme 2 (ACE2) receptor on the surface of the host cell (Gallagher and Buchmeier, 2001; Yan et al., 2020). The S protein comprises two functional domains (S1 and S2) (Fig. 1a and c). The S1 domain forms the “head” of the protein and is responsible for ACE2 receptor binding. The S2 is a transmembrane domain and mediates the fusion of the viral and host cell membranes, a key point for virus infection (Gallagher and Buchmeier, 2001; Yan et al., 2020).

Upon binding to ACE2, the viral S protein is cleaved at the S2 domain by the Transmembrane Protease Serine 2 (TMPRSS2), in a process known as S protein priming. S2 cleavage allows S protein activation, fusion of viral and host cell membranes and direct entry of the viral RNA into the cytoplasm (Hoffmann et al., 2020) (Fig. 1b). Alternatively, viral infection can occur through the endocytic pathway, where the ACE2-virus complex is translocated into the host cell through endosomes (Fig. 1b). In this case, S protein is cleaved at the S2 domain by the endosomal cysteine proteases cathepsin B and cathepsin L (CTSB/L) and the viral RNA is released into the cytoplasm after fusion of viral and endosomal membranes (Hoffmann et al., 2020). Once the viral genomic RNA is released into the cytoplasm, it is translated by host cell ribosomes into viral proteins required for viral replication. Then, the viral genome is replicated and the four structural proteins (S, E, M and N) are translated through the endoplasmatic reticulum and Golgi complex of the host cell. Finally, the genomic RNA and the structural proteins are assembled into new viral particles that are released through exocytosis (Fig. 1b) (Du et al., 2009; Hoffmann et al., 2020).

Despite sharing the same infectious mechanism, the S protein of SARS-CoV-2 contains two distinctive features that are not present in the S protein of SARS-CoV (Fig. 1c). First, the S protein of SARS-CoV-2 has acquired mutations in five of the six residues critical for ACE2 binding, which increases 10-20-fold the binding affinity of SARS-CoV-2 S protein to ACE2 compared to the S protein of SARS-CoV (Gupta et al., 2020; Wrapp et al., 2020). This increase in binding affinity is thought to increase SARS-CoV-2 transmissibility and severity of COVID-19. Second, the S protein of SARS-CoV-2 contains a furin polybasic cleavage site between S1 and S1 (S1/S2) that is not present in the S protein of SARS-CoV (Fig. 1c). Furin-mediated cleavage generates a polybasic site that has been recently demonstrated to bind to Neutrophilin 1 (NRP1), a member of the neuropilin family of cell surface receptors involved in essential cellular signaling cascades (Guo and Vander Kooi, 2015). This novel furin site enhances SARS-CoV-2 infectivity and broadens the ability of SARS-CoV-2 to infect multiple organs, including the heart (Cantuti-Castelvetri et al., 2020; Daly et al., 2020). Nevertheless, studies of SARS-CoV-2 entry into host cells conducted to date have mainly focused on ACE2 and there is little knowledge about the virus and host mechanisms that determine cellular entry of SARS-CoV-2.
Fig. 1: SARS-CoV-2 structure and pathogenesis (a) The viral positive-sense single-stranded RNA (ssRNA) genome is bound to nucleocapsid (N) proteins and wrapped inside a spherical lipid bilayer, where the structural spike (S), envelope (E) and membrane (M) proteins are anchored. (b) SARS-CoV-2 S protein binds to ACE2 receptor, allowing viral entry into host cell either by direct fusion with the host cell membrane (1a) or via endocytosis with later viral release from the endocytic vesicle to the cytoplasm (1b). Positive ssRNA is released (2), partially translated into SARS-CoV-2 polymerase protein by host cell ribosomes (3). SARS-CoV-2 genome is then replicated and structural SARS-CoV-2 proteins (S, M, E and N) are synthesized (4). Structural proteins S, M and E are taken to the host cell endoplasmic reticulum (ER) membrane (5) and later combined with N protein (6). The complex is processed in the Golgi and all elements are incorporated into a new virion (7) that is secreted through exocytosis (8). (c) SARS-CoV and SARS-CoV-2 S proteins share the same structure with the S1 domain, responsible for ACE2 binding mediated by the receptor-binding domain (RBD); and the S2 domain, responsible for membrane fusion. However, compared to SARS-CoV, the S protein of SARS-CoV-2 has two remarkable features. On one hand, five of the six residues within the S1 RBD that are crucial for ACE2 binding are mutated, which increases SARS-CoV-2 binding affinity to ACE2. On the other hand, SARS-CoV-2 shows a novel furin cleavage site at the S1/S2 boundary that increases infectivity and the ability to infect multiple organs.
SARS-CoV-2 and the Cardiovascular System

Coronaviruses are known for their impact on the respiratory tract. However, SARS-CoV-2, the most recent coronavirus also presents a high tropism for the cardiovascular system. In fact, based on all the information gathered so far, it has been observed that about 20-25% of COVID-19 patients develop cardiovascular complications such as myocarditis, arrhythmias, myocardial injury and thromboembolism (Guzik et al., 2020; Huang et al., 2020; Nishiga et al., 2020) (Fig. 2). Although the underlying mechanisms are not well understood, it has been postulated that myocardial injury may be the result from either direct or indirect mechanisms discussed in the sections below.

Potential Mechanisms Underlying Cardiovascular Dysfunction in COVID-19 Direct Myocardial Infection by SARS-CoV-2

The ability of SARS-CoV-2 to infect cardiomyocytes has been demonstrated in vitro using human induced pluripotent stem cells-derived cardiomyocytes (hiPS-CMs), where SARS-CoV-2 infection led to sarcomeric structural disruptions affecting the contractile machinery of the myocardium and suspension of cell beating (Bojkova et al., 2020). Moreover, numerous studies have also presented in vivo histological evidence of direct viral infection in the heart. An autopsy case series of 27 patients revealed that, although the highest concentration of SARS-CoV-2 genomic RNA was found in the lungs; the heart, kidney and liver also showed substantial amounts of viral RNA (Puelles et al., 2020). In another autopsy analysis involving 39 patients with COVID-19, a high viral load (above 1000 copies) was detected in the myocardium of 41% of the patients (Lindner et al., 2020).

As previously mentioned, upon SARS-CoV-2 binding to ACE2, viral entry into the host cell can be mediated by either TMPRSS2 orCTSβ/L, priming of S protein (Fig. 1b and c). According to the latest version of RNA-sequencing data from the Genotype-Tissue Expression (GTEx) project, ACE2 and CTSβ/L are highly expressed in the heart and coronary arteries whereas TMPRSS2 expression is almost undetectable (GTEx Portal, 2020). Consistent with GTEx results, single-cell RNA-sequencing revealed that ACE2 and CTSβ/L are highly expressed in cardiomyocytes, while TMPRSS2 is not expressed (Litvihuková et al., 2020). Based on these observations, a conceivable hypothesis is that S protein priming by CTSβ/L and the subsequent activation of the endocytic pathway could mediate SARS-CoV-2 infection of cardiomyocytes. Alternatively, SARS-CoV-2 infection could also be explained by the novel furin cleavage site. As described above, furin-mediated cleavage generates a polybasic site that is recognized and bound by NRPI protein, a broadly distributed cell surface receptor also expressed in cardiomyocytes (GTEx Portal, 2020).

ACE2 Downregulation

SARS-CoV-2 infection is mediated by ACE2, an important member of the renin-angiotensin-aldosterone system (RAAS) involved in blood pressure control, sodium reabsorption, inflammation and fibrosis (Vaduganathan et al., 2020) (Fig. 2, middle). In the classic RAAS, angiotensinogen is cleaved by the enzyme renin to form the inactive angiotensin (Ang) I, which is then cleaved by ACE to generate the physiologically active Ang II. Among other functions, Ang II promotes the release of pro-inflammatory cytokines such as interleukin (IL)-6, IL-1β and Tumor Necrosis Factor (TNF)-α. These adverse pro-inflammatory properties of Ang II are counteracted by ACE2 through the degradation of Ang II to the protective Ang I-7 (Ingraham et al., 2020).

ACE2 is expressed in many organs, including the heart (GTEx Portal, 2020; Litvihuková et al., 2020). Several studies have shown that SARS-CoV-2 infection downregulates ACE2 expression on infected cells, thereby shifting RAAS toward the pro-inflammatory ACE2/Ang II axis (Banu et al., 2020). Overproduction of Ang II has been linked to cardiac diseases such as heart failure and atrial fibrillation (Ingraham et al., 2020). ACE2 knockout mice shown abnormal heart function and increased Ang II levels, leading to severe cardiac contractility defects, myocardial hypertrophy and heart failure (Crackower et al., 2002; Oudit et al., 2007; Zhong et al., 2010). In the context of COVID-19, early studies found a progressive increase in Ang II and IL-6 levels among COVID-19 hospitalized patients, with the highest levels observed among non-survivors (Miesbach, 2020; Wu et al., 2020b). Ang II levels have additionally been shown to be elevated in several conditions such as hypertension, diabetes mellitus and CVD. The basal inflammation present in patients with these pre-existing conditions could exacerbate SARS-CoV-2 inflammatory response, activating the so-called cytokine storm (explained in the section below) ending in multi-organ failure. Therefore, inherent RAAS-ACE2 dysregulation in conditions such as hypertension, diabetes and CVD could explain why these comorbidities are frequently observed in severe COVID-19 cases.

Cytokine Storm

SARS-CoV-2 entry into host cells activates the immune system and the release of pro-inflammatory cytokines such as IL-6, IL-1β TNF-α that, among other functions, activate immune cells such as macrophages and T lymphocytes to fight the virus (Moore and June, 2020; Zhang et al., 2020). Upon SARS-CoV-2 infection in the respiratory system, approximately 80% of patients present a proper antiviral immune response successfully eliminating
the virus (Polidoro et al., 2020). However, some COVID-19 patients develop an exaggerated immune response with massive release of pro-inflammatory cytokines (Moore and June, 2020; Zhang et al., 2020). Increased levels of pro-inflammatory cytokines have been associated to COVID-19 severity and worse prognosis. Several clinical studies reported that deceased COVID-19 patients present significantly higher levels of pro-inflammatory cytokines compared to patients who recover from the disease (Moore and June, 2020; Zhang et al., 2020).

Although triggered by local infection, the magnified immune response in the lungs further increases lung inflammation, leading to ARDS. This increase in lung inflammation also results in a loop of systemic inflammation characterized by an overproduction of pro-inflammatory cytokines, also known as cytokine storm, that activate dysfunctional remodeling pathways in multiple organs, including the heart (Huang et al., 2020; Xu et al., 2020). In fact, it has been described that increased levels of pro-inflammatory cytokines TNF-β, IL-1α and IL-6 in the heart may contribute to the development of myocardial injury (Bozkurt et al., 1998; Hasdai et al., 1996; Matsumori et al., 1994; Palmer et al., 1995). Additionally, these pro-inflammatory cytokines could lead to electrical disturbances in the heart, as they have been shown to negatively regulate the expression of important proteins for both cardiac excitation-contraction and cell-cell coupling (Pinto and Boyden, 1999). Therefore, it is not surprising that multiple clinical studies now report that severely COVID-19 infected patients show a significant arrhythmogenic burden including heart palpitations and tachycardia (Driggin et al., 2020; Lang et al., 2020; Nishiga et al., 2020).

In addition to the direct inflammatory damage, it has also been proposed that the cytokine storm could contribute to lymphopenia (abnormally low levels of lymphocytes in the blood) observed in a significant proportion of severe COVID-19 cases (Fathi and Rezaei, 2020). Lymphopenia has been previously associated with cardiovascular diseases and it has been recommended to use the relative lymphocyte concentration as a prognostic marker in patients with acute and chronic coronary artery disease (Ommen et al., 1998).

Coagulation Abnormalities and Thrombotic Events

It has been shown that SARS-CoV-2 infection, RAAS alterations and the cytokine storm simultaneously trigger the production of the coagulation factors thrombin and fibrinogen that increase blood coagulability, a major risk factor for atherothrombotic cardiovascular events (Hiraiwa and Van Eeden, 2014). To counteract thrombi formation, blood clots are regularly degraded by specific enzymes, which leads to an increase in fibrin degradation products such as D-dimer (Bikdeli et al., 2020). Recent reports in COVID-19 patients also highlight the presence of aberrant coagulation products such as D-dimer, whose elevated levels were correlated with COVID-19 disease severity (Bikdeli et al., 2020; Connors and Levy, 2020; Tang et al., 2020; F. Zhou et al., 2020). This increase in coagulation parameters in COVID-19 patients suggests the presence of a hypercoagulable state that can result in thromboembolic events. A prospective autopsy study revealed that 7 of 12 patients who died of COVID-19 presented deep vein thrombosis, even when venous thromboembolism was not suspected prior to death (Wichmann et al., 2020). Interestingly, another study with 183 COVID-19 patients found that 71% of those who died met the criteria for disseminated intravascular coagulation from the International Society on Thrombosis and Haemostasis (Taylor et al., 2001), compared with only 0.6% of COVID-19 patients that survived (Tang et al., 2020). Coagulation abnormalities could also affect cardiac blood flow or destabilize existing coronary artery plaques, known triggers of myocardial ischemia (Libby et al., 2018). Additionally, the acute immobilization of critically ill patients in intensive care unit could also contribute to the hypercoagulable state observed in COVID-19 patients.

Hypoxia

Inflammation and lung injury can also lead to hypoxemia, or low circulating oxygen levels. As described earlier, the acute immune response in the lungs induces inflammatory damage to endothelial alveolocapillary membrane, increasing pulmonary permeability and edema that leads to ARDS (Xu et al., 2020). Fluid entry into the airspaces impairs gaseous exchanges between the respiratory and vascular systems, leading to dyspnea. Dyspnea has been reported in over 50% of severe COVID-19 cases, being more common in deceased COVID-19 patients compared to those who recovered from the disease (Allali et al., 2020; Chen et al., 2020). In the context of the cardiovascular system, hypoxemia causes reduced energy supply to cardiomyocytes, which could promote the development of myocardial injury, including arrhythmia and shock (Allali et al., 2020; Wang et al., 2020).

Drug-Induced Cardiovascular Toxicity

Other than the aforementioned mechanisms for induced effects of COVID-19 in the cardiovascular system, the potential drug-disease interactions in patients with COVID-19 have become a matter of debate. On one hand, some of the potential anti-SARS-CoV-2 drugs used to treat patients with COVID-19 have been described to induce cardiovascular toxicity or interact with other cardiovascular medications (Sanders et al., 2020) (Table 1). On the other hand, it is still unknown whether usage of common cardiovascular drugs such as ACE inhibitors or Ang II Receptor Blockers (ARBs)
influence susceptibility and/or severity of COVID-19 (Vaduganathan et al., 2020).

**Underlying Cardiovascular Comorbidities**

COVID-19 has been strongly associated with CVD, similar to previous coronavirus respiratory disease outbreaks. Clinical studies conducted so far have identified that the presence of pre-existing CVD or its associated risk factors (such as hypertension and diabetes mellitus) are highly prevalent comorbidities among patients with COVID-19, especially in critically ill patients (Nishiga et al., 2020). A meta-analysis of 1,527 patients with COVID-19 reported that 17.1% had a history of hypertension, 9.7% of diabetes and 16.4% of CVD (Li et al., 2020). A significantly larger report from the Chinese Center for Disease Control and Prevention described clinical comorbidities in 44,672 patients with COVID-19. In the study, the overall case fatality rate was 2.3% and it was significantly higher in patients with CVD (10.5%) (Wu and McGoogan, 2020).

![Fig. 2: Possible mechanisms of cardiovascular injury due to COVID-19 SARS-CoV-2 primarily infects the respiratory system (left panel). SARS-CoV-2 infection downregulates ACE2 that, in combination with immune cell over-activation and massive release of pro-inflammatory cytokines (cytokine storm), lead to lung failure and Acute Respiratory Distress Syndrome (ARDS) in severe COVID-19 cases. In the cardiovascular system (right panel), cardiac complications can be triggered by direct SARS-CoV-2 infection or by indirect mechanisms during COVID-19. Immune over-activity can precipitate blood clot formation leading to thromboembolism. Also, acute inflammation can promote the development of myocardial injury including myocarditis, arrhythmia and heart failure. ARDS-derived hypoxia can also lead to cardiac injury due to the reduced energy supply to cardiomyocytes in patients with this condition. Moreover, some medications that have been proposed as treatments for COVID-19 have cardiovascular toxicity. Finally, pre-existing cardiovascular comorbidities such as hypertension and coronary heart disease may also play an important pathophysiological role in the development of cardiovascular complications during COVID-19](image-url)
In addition to being widely prevalent, CVD can also be triggered by SARS-CoV-2 infection in patients with no prior history of heart disease. Indeed, several studies of hospitalized COVID-19 patients without previous history of cardiovascular disease observed that patients with raised cardiac injury biomarkers, such as troponin TnI and TnT, had significantly higher mortality rates (~50-60%) compared to those with normal levels (~4.5-9%) (Guo et al., 2020; Shi et al., 2020).

**Potential Long-Term Cardiac Consequences**

COVID-19 is a very recent pandemic and the long-term cardiac outcome of patients who recover from this condition remain to be seen. While the immediate cardiac damage has already been manifested by severe COVID-19 patients, the long-term effects on the cardiovascular system remain currently unknown. Due to the considerable similarity between SARS-CoV-2 and SARS-CoV, some important insights can be gleaned from previous experience with SARS. For example, in a 12-years follow-up study, about 40% of patients who had recovered from SARS presented cardiovascular abnormalities (Wu et al., 2017). Therefore, patients who recover from severe COVID-19 could be at higher risk of developing CVD, reinforcing the need for additional studies to gain insight in the molecular mechanisms leading to cardiac injury in COVID-19 patients. A better understanding in COVID-19 pathophysiology would also promote the development of screening and therapeutic interventions to prevent COVID-19-associated cardiac injury in the future.

**Conclusion**

SARS-CoV-2, the newest member of the β-coronavirus family, is a highly transmissible virus that has caused a global pandemic with more than 1.8 million deaths as of January 7, 2021. Although COVID-19 is primarily a respiratory illness and ARDS is the main clinical complication in severe COVID-19 cases, approximately 20-25% of patients also develop cardiac complications such as myocardial injury, arrhythmia, cardiac arrest, cardiomyopathy, heart failure, or cardiogenic shock. In addition, a high prevalence of pre-existing CVD and its associated risk factors have been observed in COVID-19 patients, which predispose to an increased risk of severe COVID-19 disease and mortality. Even though our knowledge about COVID-19 has expanded rapidly, there are several aspects regarding the pathophysiology of the disease that are not completely understood. Limited results presented so far suggest that ACE2 and inflammation -either local or systemic- play a crucial role in prompting and potentiating existing and new cardiac functional abnormalities. In summary, we suggest that future studies should focus on the understanding of the molecular mechanisms that drive COVID-19 related cardiac complications. Also, it would be interesting to examine the role of CVD-susceptibility variants in COVID-19-induced cardiovascular manifestations.

**Acknowledgement**

We acknowledge S. Pagans, M. Verges and B. del Olmo for their contribution in reviewing the original draft.

**Funding Information**

This work was supported by the Biomedical Research Institute from Girona (IDIBGI), University Hospital Dr. Josep Trueta from Girona and Obra Social La Caixa. M.P.A. is also supported by Fondo Superá COVID-19 from Banco de Santander. The funders had no role in the design, preparation, review or approval of the manuscript.

**Author contributions**

Mel·lina Pinsach-Abuin: Has reviewed the relevant articles on SARS-CoV-2 published to date with the aim to provide a simplified overview of the molecular mechanisms underlying cardiovascular involvement in COVID-19. She has contributed to the conceptualization, writing the original draft, reviewing and editing.

Ramon Brugada Terradellas: Has contributed to writing the original draft, reviewing and editing.
Ethics

This article is original and contains unpublished material. The corresponding author confirms that all of the other authors have read and approved the manuscript and there are no ethical issues involved.

References


doi.org/10.1038/s41591-020-0968-3

doi.org/10.1093/cvr/cvaa106


doi.org/10.1016/j.ahj.2020.04.025

doi.org/10.1007/s00392-020-01626-9

doi.org/10.1016/j.jacc.2018.08.1043


doi.org/10.1016/S0065-3527(06)66005-3


